May 8, 2015: The network is inviting applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system.
A maximum of $25,000 will be awarded for each catalyst grant.
Applications may be submitted by any investigator associated with a Canadian Institution.
Relevant Research Areas:
Three categories of Connection applications will be considered:
- Novel gene supported by genetic evidence (mutations in the same gene in unrelated patients with a similar phenotype) and functional data is being rapidly sought prior to publication.
- Candidate gene for a rare disease in a single patient/family/isolated population such that additional functional data is necessary to support disease-causation. Two types of candidate genes will be considered:
Known disease gene that is of therapeutic or biological interest to a unique Canadian population or community (e.g. Hutterite, First Nation, French Canadian, patient advocacy group etc.).
- Candidate gene has not previously been associated with disease; and,
- Novel mutation in known disease gene causing a very distinct disease secondary to a presumed alternate mechanism.
- Therapeutic opportunities will include projects that propose to develop a model asset for drug screening or develop a model to evaluate efficacy of a treatment; and,
- Biological interest will include those genes published by a Canadian group for which further study has the potential to impact a new area of biology.
There is no deadline. Applications are accepted on an ongoing basis.
A Connection Application may be submitted to the RDMM Network email@example.com.
All the information about the RDMM network can be found at the network website.
Co-Chairs, Clinical Advisory Committee